Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics is refocusing its pipeline and shedding a lot of staff. This should allow the early-stage biotech to stretch its cash a bit further.

After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?

Eli Lilly

Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and Co (NYSE:LLY). An upfront $250 million cash and paper payment could balloon to $600 million based on milestones.

Beam Therapeutics up 10% on $600m Lilly deal

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam's Cash Runway to the Second Half of 2026 Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam's Cash Runway to the Second Half of 2026

Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease

Beam recently announced a reorganization that involves layoffs and a narrowing of its pipeline. The company lost $82.8 million in the second quarter.

5 Reasons Beam Therapeutics Remains a Risky Stock

Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Cathie Wood has made big bets on base-editing stocks, including recent purchases of Beam Therapeutics. However, Beam announced a reprioritization of its pipeline last week, raising concerns for investors.

Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?

Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. The company has chosen to cut out several programs to conserve cash and prioritize long-term value for shareholders; Cash runway extended into 2026. The global sickle cell disease market is projected to reach $9.84 billion by 2030.

Beam: Opportunity Based On SCD Data Readout In 2024

Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty of money and some help from Pfizer, too.

Beam Therapeutics Stock: Bear vs. Bull

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%.

BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank

Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructuring plan.

Beam Therapeutics to cut 20% of workforce as part of restructuring plan

Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash runway into 2026. The Cambridge, Mass.

Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Editas Medicine

Don't buy biotech stocks unless your portfolio is properly diversified already. Beam Therapeutics might eventually have a competitive advantage in manufacturing.

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

BEAM Focuses on Developing Gene Drug for Growth

Recursion Pharmaceuticals

Investor Cathie Wood has an eye for powerful trends in high-tech areas of the market. She has been hitting the buy button lately on Beam Therapeutics and Recursion Pharmaceuticals.

2 Cathie Wood Stocks I'm Bullish On

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

bluebird bio

CRISPR Therapeutics

Pfizer

Vertex Pharmaceuticals

In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene therapies.

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?

Caribou Biosciences

Growth stocks have rebounded to a degree this year. Even so, developmental biotech companies have still had a rough year as a whole in 2023.

2 Magnificent Growth Stocks to Buy On the Dip

SomaLogic

Beam Therapeutics is pioneering a promising type of gene editing. Recursion Pharmaceuticals is harnessing AI to improve drug discovery.

3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too

Wave Life Sciences

Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.

2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss

Cathie Wood is buying shares of Beam Therapeutics even though they are down. Stocks can fall for all sorts of reasons that aren't relevant in the long term.

This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.

Pacific Biosciences of California

Spotify

Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of California, a genetic sequencing company, multiple times this week.

Cathie Wood's Buying These 3 Stocks Hand Over Fist

First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences:

Beam Therapeutics to Participate in Upcoming September Investor Conferences

COMPASS Pathways

908 Devices

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

News for Beam Therapeutics Stock (BEAM)